Metastatic renal cancer is not sensitive to radiotherapy and chemotherapy, and the effective rate of immunotherapy with interferon and interleukin-2 (IL-2) as first-time clinical treatment is only 15% (Zou et al., 2019). This evidence concerns the gene IL2 and renal carcinoma.